Skip to main content

Advertisement

SpringerLink
Log in

Extrahepatic Manifestations of Hepatitis B

  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Hepatitis B virus (HBV) infection is a global public health issue. While cirrhosis and hepatocellular carcinoma commonly affect patients with chronic HBV, extrahepatic manifestations are often unappreciated.

Recent Findings

Extrahepatic manifestations can be variable in presentation but include several commonly described syndromes including HBV-related nephropathy, vasculitides, dermatitis, and arthritis. However, recently described entities include hematologic and neurologic manifestations.

Summary

The primary immune-mediated mechanism common to many extrahepatic manifestations involves viral antigen-triggered immune complex formation. Initiation of antiviral treatment is associated with clinical response in most cases of extrahepatic disease; thus, recognition of these manifestations is essential to mitigating associated morbidity and mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Vyas AK, Lslam M, Garg G, Singh AK, Trehanpati N. Humoral immune responses and hepatitis B infection. Dig Dis. 2021;39(5):516–25. https://doi.org/10.1159/000514274.

    Article  PubMed  Google Scholar 

  2. Yuen M-F, Chen D-S, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, et al. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4(1):18035. https://doi.org/10.1038/nrdp.2018.35.

    Article  PubMed  Google Scholar 

  3. Sheena BS, Hiebert L, Han H, Ippolito H, Abbasi-Kangevari M, Abbasi-Kangevari Z, et al. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796–829. https://doi.org/10.1016/S2468-1253(22)00124-8.

    Article  Google Scholar 

  4. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5(3):215–29. https://doi.org/10.1038/nri1573.

    Article  CAS  PubMed  Google Scholar 

  5. Jennette JC, Falk R, Bacon P, Basu N, Cid M, Ferrario F, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. 2013.

  6. Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine. 2005;84(5):313–22. https://doi.org/10.1097/01.md.0000180792.80212.5e.

    Article  PubMed  Google Scholar 

  7. Hočevar A, Tomšič M, Perdan PK. Clinical approach to diagnosis and therapy of polyarteritis nodosa. Curr Rheumatol Rep. 2021;23(3):14. https://doi.org/10.1007/s11926-021-00983-2.

    Article  PubMed  Google Scholar 

  8. Wang CR, Tsai HW. Human hepatitis viruses-associated cutaneous and systemic vasculitis. World J Gastroenterol. 2021;27(1):19–36. https://doi.org/10.3748/wjg.v27.i1.19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database. Arthritis Rheum. 2010;62(2):616–26. https://doi.org/10.1002/art.27240.

    Article  PubMed  Google Scholar 

  10. Trepo C, Guillevin LC. Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. J Autoimmun. 2001;16(3):269–74. https://doi.org/10.1006/jaut.2000.0502.

    Article  CAS  PubMed  Google Scholar 

  11. Naniwa T, Maeda T, Shimizu S, Ito R. Hepatitis B virus-related polyarteritis nodosa presenting with multiple lung nodules and cavitary lesions. Chest. 2010;138(1):195–7. https://doi.org/10.1378/chest.09-2579.

    Article  PubMed  Google Scholar 

  12. Nemoto M, Nishioka K, Fukuoka J, Aoshima M. Hepatitis B virus-associated vasculitis: multiple cavitary masses in the lung mimicking granulomatous polyangiitis. Intern Med. 2019;58(20):3013–7. https://doi.org/10.2169/internalmedicine.3012-19.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Shields LBE, Burge M, Hunsaker JC. Sudden death due to polyarteritis nodosa. Forensic Sci Med Pathol. 2012;8(3):290–5. https://doi.org/10.1007/s12024-011-9290-1.

    Article  PubMed  Google Scholar 

  14. Iino T, Eguchi K, Sakai M, Nagataki S, Ishijima M, Toriyama K. Polyarteritis nodosa with aortic dissection: necrotizing vasculitis of the vasa vasorum. J Rheumatol. 1992;19(10):1632–6.

    CAS  PubMed  Google Scholar 

  15. Sergent JS, Lockshin MD, Christian CL, Gocke DJ. Vasculitis with hepatitis B antigenemia: long-term Observations in Nine Patients. Medicine. 1976;55(1):1–18.

    Article  CAS  PubMed  Google Scholar 

  16. Duffy J, Lidsky MD, Sharp JT, Davis JS, Person DA, Hollinger FB, et al. Polyarthritis, polyarteritis and hepatitis B. Medicine. 1976;55(1):19–37.

    Article  CAS  PubMed  Google Scholar 

  17. Shusterman N, London WT. Hepatitis B and immune-complex disease. N Engl J Med. 1984;310(1):43–6. https://doi.org/10.1056/nejm198401053100110.

    Article  CAS  PubMed  Google Scholar 

  18. Guillevin L, Lhote F, Cohen P, Sauvaget F, Jarrousse B, Lortholary O, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine. 1995;74(5):238–53. https://doi.org/10.1097/00005792-199509000-00002.

    Article  CAS  PubMed  Google Scholar 

  19. Michalak T. Immune complexes of hepatitis B surface antigen in the pathogenesis of periarteritis nodosa. A study of seven necropsy cases. Am J Pathol. 1978;90(3):619–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Fye KH, Becker MJ, Theofilopoulos AN, Moutsopoulos H, Feldman JL, Talal N. Immune complexes in hepatitis B antigen-associated periarteritis nodosa. Detection by antibody-dependent cell-mediated cytotoxicity and the Raji cell assay. Am J Med. 1977;62(5):783–91. https://doi.org/10.1016/0002-9343(77)90884-1.

    Article  CAS  PubMed  Google Scholar 

  21. Gocke D, Hsu K, Morgan C, Bombardieri S, Lockshin M, Christian C. Association between polyarteritis and Australian antigen. Lancet. 1970;296(7684):1149–53. https://doi.org/10.1016/S0140-6736(70)90339-9.

    Article  Google Scholar 

  22. Sergent JS. Extrahepatic manifestations of hepatitis B infection. Bull Rheum Dis. 1983;33(6):1–6.

    CAS  PubMed  Google Scholar 

  23. Rogers RB, Graham Smith JJ, Chalker DK. Hepatitis and the skin. J Am Acad Dermatol. 1982;7(4):552–4. https://doi.org/10.1016/S0190-9622(82)80257-0.

    Article  CAS  PubMed  Google Scholar 

  24. Mirise RT, Kitridou RC. Arthritis and hepatitis. West J Med. 1979;130(1):12–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Janssen HL, van Zonneveld M, van Nunen AB, Niesters HG, Schalm SW, de Man RA. Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome. Eur J Gastroenterol Hepatol. 2004;16(8):801–7. https://doi.org/10.1097/01.meg.0000108362.41221.57.

    Article  CAS  PubMed  Google Scholar 

  26. Tang MBY, Liew KVS, Ng PPL, Tan SH, Ng SK. Cutaneous polyarteritis nodosa associated with precore mutant hepatitis B infection. Br J Dermatol. 2003;149(4):914–5. https://doi.org/10.1046/j.1365-2133.2003.05538.x.

    Article  CAS  PubMed  Google Scholar 

  27. Wartelle-Bladou C, Lafon J, Trépo C, Pichoud C, Picon M, Pellissier J-F, et al. Successful combination therapy of polyarteritis nodosa associated with a pre-core promoter mutant hepatitis B virus infection. J Hepatol. 2001;34(5):774–9. https://doi.org/10.1016/S0168-8278(00)00088-X.

    Article  CAS  PubMed  Google Scholar 

  28. Miguelez M, Bueno J, Laynez P. Polyarteritis nodosa associated with precore mutant hepatitis B virus infection. Ann Rheum Dis. 1998;57(3):173. https://doi.org/10.1136/ard.57.3.173.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Dienstag JL. Immunopathogenesis of the extrahepatic manifestations of hepatitis B virus infection. Springer Semin Immunopathol. 1981;3(4):461–72. https://doi.org/10.1007/bf01951493.

    Article  CAS  PubMed  Google Scholar 

  30. McElgunn PSJ. Dermatologic manifestations of hepatitis B virus infection. Journal of the American Academy of Dermatology. 1983;8(4):539–48. https://doi.org/10.1016/S0190-9622(83)80058-9.

    Article  CAS  PubMed  Google Scholar 

  31. Stone JH. Polyarteritis nodosa. JAMA. 2002;288(13):1632–9. https://doi.org/10.1001/jama.288.13.1632.

    Article  PubMed  Google Scholar 

  32. Hekali P, Kajander H, Pajari R, Stenman S, Somer T. Diagnostic significance of angiographically observed visceral aneurysms with regard to polyarteritis nodosa. Acta Radiol. 1991;32(2):143–8. https://doi.org/10.1177/028418519103200212.

    Article  CAS  PubMed  Google Scholar 

  33. Puéchal X. Polyarteritis nodosa: state of the art. Joint Bone Spine. 2022;89(4):105320. https://doi.org/10.1016/j.jbspin.2021.105320.

    Article  CAS  PubMed  Google Scholar 

  34. Howard T, Ahmad K, Swanson JA, Misra S. Polyarteritis nodosa. Tech Vasc Interv Radiol. 2014;17(4):247–51. https://doi.org/10.1053/j.tvir.2014.11.005.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Frohnert PP, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med. 1967;43(1):8–14. https://doi.org/10.1016/0002-9343(67)90144-1.

    Article  CAS  PubMed  Google Scholar 

  36. Pinto PC, Hu E, Bernstein-Singer M, Pinter-Brown L, Govindarajan S. Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer. 1990;65(4):878–84.

    Article  CAS  PubMed  Google Scholar 

  37. Lam KC, Lai CL, Ng RP, Trepo C, Wu PC. Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med. 1981;304(7):380–6. https://doi.org/10.1056/nejm198102123040702.

    Article  CAS  PubMed  Google Scholar 

  38. Guillevin L, Lhote F, Leon A, Fauvelle F, Vivitski L, Trepo C. Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol. 1993;20(2):289–98.

    CAS  PubMed  Google Scholar 

  39. Guillevin L, Lhote F, Sauvaget F, Deblois P, Rossi F, Levallois D, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis. 1994;53(5):334–7. https://doi.org/10.1136/ard.53.5.334.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Guillevin L, Mahr A, Cohen P, Larroche C, Queyrel V, Loustaud-Ratti V, et al. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus–related polyarteritis nodosa. Arthritis Care Res. 2004;51(3):482–7. https://doi.org/10.1002/art.20401.

    Article  CAS  Google Scholar 

  41. Kruger M, Böker KH, Zeidler H, Manns MP. Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b. J Hepatol. 1997;26(4):935–9. https://doi.org/10.1016/s0168-8278(97)80263-2.

    Article  CAS  PubMed  Google Scholar 

  42. Erhardt A, Sagir A, Guillevin L, Neuen-Jacob E, Häussinger D. Successful treatment of hepatitis B virus associated polyarteritis nodosa with a combination of prednisolone, α-interferon and lamivudine. J Hepatol. 2000;33(4):677–83. https://doi.org/10.1016/S0168-8278(00)80025-2.

    Article  CAS  PubMed  Google Scholar 

  43. Combes B, Shorey J, Barrera A, Stastny P, Eigenbrodt EH, Hull AR, et al. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet. 1971;2(7718):234–7. https://doi.org/10.1016/s0140-6736(71)92572-4.

    Article  CAS  PubMed  Google Scholar 

  44. Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. Am J Nephrol. 2004;24(2):198–211. https://doi.org/10.1159/000077065.

    Article  CAS  PubMed  Google Scholar 

  45. Shah AS, Amarapurkar DN. Spectrum of hepatitis B and renal involvement. Liver Int. 2018;38(1):23–32. https://doi.org/10.1111/liv.13498.

    Article  PubMed  Google Scholar 

  46. Kupin WL. Viral-associated GN: hepatitis B and other viral infections. Clin J Am Soc Nephrol. 2017;12(9):1529–33. https://doi.org/10.2215/cjn.09180816.

    Article  CAS  PubMed  Google Scholar 

  47. Wang R, Wu Y, Zheng B, Zhang X, An D, Guo N, et al. Clinicopathological characteristics and prognosis of hepatitis B associated membranous nephropathy and idiopathic membranous nephropathy complicated with hepatitis B virus infection. Sci Rep. 2021;11(1):18407. https://doi.org/10.1038/s41598-021-98010-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Jiang W, Liu T, Dong H, Xu Y, Liu LQ, Guan GJ, et al. Relationship between serum DNA replication, clinicopathological characteristics and prognosis of hepatitis B virus-associated glomerulonephritis with severe proteinuria by lamivudine plus adefovir dipivoxil combination therapy. Biomed Environ Sci. 2015;28(3):206–13. https://doi.org/10.3967/bes2015.027.

    Article  CAS  PubMed  Google Scholar 

  49. Fu B, Ji Y, Hu S, Ren T, Bhuva MS, Li G, et al. Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: a meta-analysis. PLoS One. 2020;15(1):e0227532. https://doi.org/10.1371/journal.pone.0227532. Meta-analysis of seven clinical trials with 182 participants examining efficacy and safety of NRTI's and interferon therapy for HBV-GN

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Takekoshi Y, Tanaka M, Miyakawa Y, Yoshizawa H, Takahashi K, Mayumi M. Free small and IgG-associated large hepatitis B e antigen in the serum and glomerular capillary walls of two patients with membranous glomerulonephritis. N Engl J Med. 1979;300(15):814–9. https://doi.org/10.1056/nejm197904123001502.

    Article  CAS  PubMed  Google Scholar 

  51. Chen L, Wu C, Fan X, Gao J, Yin H, Wang T, et al. Replication and infectivity of hepatitis B virus in HBV-related glomerulonephritis. Int J Infect Dis. 2009;13(3):394–8. https://doi.org/10.1016/j.ijid.2008.08.014.

    Article  CAS  PubMed  Google Scholar 

  52. Lai KN, Lai FM, Lo S, Ho CP, Chan KW. IgA nephropathy associated with hepatitis B virus antigenemia. Nephron. 1987;47(2):141–3. https://doi.org/10.1159/000184477.

    Article  CAS  PubMed  Google Scholar 

  53. Zhang L, Meng H, Han X, Han C, Sun C, Ye F, et al. The relationship between HBV serum markers and the clinicopathological characteristics of hepatitis B virus-associated glomerulonephritis (HBV-GN) in the northeastern chinese population. Virol J. 2012;9(1):200. https://doi.org/10.1186/1743-422X-9-200.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Gupta A, Quigg RJ. Glomerular diseases associated with hepatitis B and C. Adv Chronic Kidney Dis. 2015;22(5):343–51. https://doi.org/10.1053/j.ackd.2015.06.003.

    Article  PubMed  Google Scholar 

  55. Hirose H, Udo K, Kojima M, Takahashi Y, Miyakawa Y, Miyamoto K, et al. Deposition of hepatitis B e antigen in membranous glomerulonephritis: identification by F(ab')2 fragments of monoclonal antibody. Kidney Int. 1984;26(3):338–41. https://doi.org/10.1038/ki.1984.178.

    Article  CAS  PubMed  Google Scholar 

  56. Zhu HL, Li X, Li J, Zhang ZH. Genetic variation of occult hepatitis B virus infection. World J Gastroenterol. 2016;22(13):3531–46. https://doi.org/10.3748/wjg.v22.i13.3531.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Gherlan GS. Occult hepatitis B—the result of the host immune response interaction with different genomic expressions of the virus. World J Clin Cases. 2022;10(17):5518–30. https://doi.org/10.12998/wjcc.v10.i17.5518.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Yu F, Li G, Hao W, Hu W. Hepatitis B virus-related glomerulonephritis with positive and negative serum HBsAg: different clinicopathologic characteristics of two clinical subtypes. Int J Gen Med. 2021;14:3069–77. https://doi.org/10.2147/ijgm.S318087. Retrospective review of 101 renal biopsies of patients with HBV-GN showing that serum HBsAg positivity is associated with a more severe disease course

    Article  PubMed  PubMed Central  Google Scholar 

  59. Lai KN, Ho RTH, Tam JS, Lai FM. Detection of hepatitis B virus DNA and RNA in kidneys of HBV-related glomerulonephritis. Kidney Int. 1996;50(6):1965–77. https://doi.org/10.1038/ki.1996.519.

    Article  CAS  PubMed  Google Scholar 

  60. Diao Z, Ding J, Yin C, Wang L, Liu W. Purified hepatitis B virus induces human Mesangial cell proliferation and extracellular matrix expression In Vitro. Virol J. 2013;10(1):300. https://doi.org/10.1186/1743-422X-10-300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. KDIGO. 2021 Clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4s):S1–s276. https://doi.org/10.1016/j.kint.2021.05.021.

    Article  Google Scholar 

  62. Lai KN, Li PKT, Lui SF, Au TC, Tam JSL, Tong KL, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med. 1991;324(21):1457–63. https://doi.org/10.1056/nejm199105233242103.

    Article  CAS  PubMed  Google Scholar 

  63. Huang C-W, Lin C-H, Chuang Y-W, Yang S-S, Lee T-Y, Yeh H-Z, et al. Association of hepatitis B virus infection and glomerulonephritis in a HBV-endemic area: a population-based study. Adv Dig Med. 2018;5(4):121–6. https://doi.org/10.1002/aid2.13092.

    Article  Google Scholar 

  64. Su C-W. Hepatitis B virus and glomerulonephritis: two silent killers. Adv Dig Med. 2018;5(4):111–2. https://doi.org/10.1002/aid2.13100.

    Article  Google Scholar 

  65. Lai KN, Lai FM, Tam JS, Vallance-Owen J. Strong association between IgA nephropathy and hepatitis B surface antigenemia in endemic areas. Clin Nephrol. 1988;29(5):229–34.

    CAS  PubMed  Google Scholar 

  66. Iida H, Izumino K, Asaka M, Fujita M, Takata M, Sasayama S. IgA nephropathy and hepatitis B virus. IgA nephropathy unrelated to hepatitis B surface antigenemia. Nephron. 1990;54(1):18–20. https://doi.org/10.1159/000185803.

    Article  CAS  PubMed  Google Scholar 

  67. Elewa U, Sandri AM, Kim WR, Fervenza FC. Treatment of hepatitis B virus-associated nephropathy. Nephron Clin Pract. 2011;119(1):c41–9; discussion c9. https://doi.org/10.1159/000324652.

    Article  CAS  PubMed  Google Scholar 

  68. Wang NS, Wu ZL, Zhang YE, Liao LT. Existence and significance of hepatitis B virus DNA in kidneys of IgA nephropathy. World J Gastroenterol. 2005;11(5):712–6. https://doi.org/10.3748/wjg.v11.i5.712.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Lai FM, Li PK, Suen MW, Lui SF, Lai KN. Crescentic glomerulonephritis related to hepatitis B virus. Mod Pathol. 1992;5(3):262–7.

    CAS  PubMed  Google Scholar 

  70. Nasri H, Mubarak M. Sudden deterioration of renal function in a patient with nephrotic syndrome and a very high hepatitis B viral DNA load. J Renal Inj Prev. 2012;1(1):39–41. https://doi.org/10.12861/jrip.2012.14.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Mareddy AS, Rangaswamy D, Vankalakunti M, Attur RP, Nagaraju SP, Koti N. Immune mediated crescentic MPGN secondary to HBV infection: a rare presentation for a common infection. Australas Med J. 2016;9(1):12–6. https://doi.org/10.4066/amj.2015.2568.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Li S-j, Xu S-t, Chen H-p, Zhang M-c, Xu F, Cheng S-q, et al. Clinical and morphologic spectrum of renal involvement in patients with HBV-associated cryoglobulinaemia. Nephrology. 2017;22(6):449–55. https://doi.org/10.1111/nep.12795.

    Article  CAS  PubMed  Google Scholar 

  73. Mazzaro C, Dal Maso L, Gragnani L, Visentini M, Saccardo F, Filippini D, et al. Hepatitis B virus-related cryoglobulinemic vasculitis: review of the literature and long-term follow-up analysis of 18 patients treated with nucleos(t)ide analogues from the Italian Study Group of Cryoglobulinemia (GISC). Viruses. 2021;13(6) https://doi.org/10.3390/v13061032.

  74. Sakai K, Morito N, Usui J, Hagiwara M, Hiwatashi A, Fukuda K, et al. Focal segmental glomerulosclerosis as a complication of hepatitis B virus infection. Nephrol Dial Transplant. 2010;26(1):371–3. https://doi.org/10.1093/ndt/gfq600.

    Article  PubMed  Google Scholar 

  75. Unverdi S, Ceri M, Köklü S, Unverdi H, Koçak E, Duranay M. Tenofovir as a first line option for prophylaxis in a patient with hepatitis B virus associated nephrotic syndrome. Ann Hepatol. 2011;10(3):372–3. https://doi.org/10.1016/S1665-2681(19)31554-6.

    Article  PubMed  Google Scholar 

  76. Harzallah A, Rahma K, Hafedh H, Mariem H, Rim G, Fethi BH, Imen G, Ezzeddine A. Hepatitis B virus-associated focal and segmental glomerular sclerosis: a rare case of tip variant. Clin Case Rep J. 2022;3(4):1–5.

    Google Scholar 

  77. Zhou T-B, Jiang Z-P. Is there an association of hepatitis B virus infection with minimal change disease of nephrotic syndrome? A clinical observational report. Ren Fail. 2015;37(3):459–61. https://doi.org/10.3109/0886022X.2014.1001711.

    Article  CAS  PubMed  Google Scholar 

  78. Fabrizi F, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis. Aliment Pharmacol Ther. 2006;24(5):781–8. https://doi.org/10.1111/j.1365-2036.2006.03041.x.

    Article  CAS  PubMed  Google Scholar 

  79. Yi Z, Wei Jie Y, Nan Z. The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: a systematic review and meta-analysis. Ann Hepatol. 2011;10(2):165–73. https://doi.org/10.1016/S1665-2681(19)31565-0.

    Article  PubMed  Google Scholar 

  80. Yang Y, Ma Y-p, Chen D-p, Zhuo L, Li W-g. A meta-analysis of antiviral therapy for hepatitis B virus-associated membranous nephropathy. PLoS One. 2016;11(9):e0160437. https://doi.org/10.1371/journal.pone.0160437.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Sun IO, Hong YA, Park HS, Choi SR, Chung BH, Park CW, et al. Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains. Korean J Intern Med. 2012;27(4):411–6. https://doi.org/10.3904/kjim.2012.27.4.411.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Cozzani E, Herzum A, Burlando M, Parodi A. Cutaneous manifestations of HAV, HBV, HCV. Ital J Dermatol Venereol. 2021;156:5–12. https://doi.org/10.23736/S2784-8671.19.06488-5.

    Article  Google Scholar 

  83. Jones AM, Warken K, Tyring SK. The cutaneous manifestations of viral hepatitis. Dermatol Clin. 2002;20(2):233–47. https://doi.org/10.1016/S0733-8635(01)00010-9.

    Article  PubMed  Google Scholar 

  84. Csepregi A, Nemesanszky E, Rojkovich B, Poor G. Rheumatoid arthritis and hepatitis B virus: evaluating the pathogenic link. J Rheumatol. 2001;28(3):474–7.

    CAS  PubMed  Google Scholar 

  85. Scully LJ, Karayiannis P, Thomas HC. Interferon therapy is effective in treatment of hepatitis B-induced polyarthritis. Dig Dis Sci. 1992;37(11):1757–60. https://doi.org/10.1007/bf01299871.

    Article  CAS  PubMed  Google Scholar 

  86. Kikuchi K, Fukuda K, Hayashi S, Maeda T, Takashima Y, Fujita M, et al. Polyarthritis presented in a patient with untreated chronic hepatitis B infection. Mod Rheumatol Case Rep. 2022;7(1):320–3. https://doi.org/10.1093/mrcr/rxac075.

    Article  Google Scholar 

  87. Hsu CS, Lang HC, Huang KY, Lin HH, Chen CL. Association of rheumatoid arthritis and hepatitis B Infection: a nationwide nested case-control study from 1999 to 2009 in Taiwan. Medicine. 2016;95(18):e3551. https://doi.org/10.1097/md.0000000000003551.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Chen Y-L, Jing J, Mo Y-Q, Ma J-D, Yang L-J, Chen L-F, et al. Presence of hepatitis B virus in synovium and its clinical significance in rheumatoid arthritis. Arthritis Res Ther. 2018;20(1):130. https://doi.org/10.1186/s13075-018-1623-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Zheng B, Li T, Lin Q, Huang Z, Wang M, Deng W, et al. Prevalence of hepatitis B surface antigen in patients with ankylosing spondylitis and its association with HLA-B27: a retrospective study from south China. Rheumatol Int. 2012;32(7):2011–6. https://doi.org/10.1007/s00296-011-1934-7.

    Article  CAS  PubMed  Google Scholar 

  90. Mihas AA, Kirby JD, Kent SP. Hepatitis B antigen and polymyositis. JAMA. 1978;239(3):221–2. https://doi.org/10.1001/jama.1978.03280300053021.

    Article  CAS  PubMed  Google Scholar 

  91. Bacon PA, Doherty SM, Zuckerman AJ. Hepatitis-B antibody in polymyalgia Rheumatica. Lancet. 1975;2(7933):476–8. https://doi.org/10.1016/s0140-6736(75)90547-4.

    Article  CAS  PubMed  Google Scholar 

  92. Elling H, Skinhøj P, Elling P. Hepatitis B virus and polymyalgia rheumatica: a search for HBsAg, HBsAb, HBcAb, HBeAg, and HBeAb. Ann Rheum Dis. 1980;39(5):511–3. https://doi.org/10.1136/ard.39.5.511.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Levo Y, Gorevic PD, Kassab HJ, Zucker-Franklin D, Franklin EC. Association between hepatitis B virus and essential mixed cryoglobulinemia. N Engl J Med. 1977;296(26):1501–4. https://doi.org/10.1056/nejm197706302962605.

    Article  CAS  PubMed  Google Scholar 

  94. Mazzaro C, Bomben R, Visentini M, Gragnani L, Quartuccio L, Saccardo F, et al. Hepatitis B virus-infection related cryoglobulinemic vasculitis. Clinical manifestations and the effect of antiviral therapy: A review of the literature. Front Oncol. 2023;13:1095780. https://doi.org/10.3389/fonc.2023.1095780. Review of clinical manifestations and treatment of HBV-related cryoglobulinemia

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Alfraji N, Upadhyaya VD, Bekampis C, Kuzyshyn H. Mixed Cryoglobulinemia syndrome (MCS) due to untreated hepatitis B with uncommon presentation: case report and literature review. BMC Rheumatol. 2020;4(1):58. https://doi.org/10.1186/s41927-020-00159-y.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Viganò M, Martin P, Cappelletti M, Fabrizi F. HBV-associated cryoglobulinemic vasculitis: remission after antiviral therapy with entecavir. Kidney Blood Press Res. 2014;39(1):65–73. https://doi.org/10.1159/000355778.

    Article  CAS  PubMed  Google Scholar 

  97. Popp JW Jr, Harrist TJ, Dienstag JL, Bhan AK, Wands JR, LaMont JT, et al. Cutaneous vasculitis associated with acute and chronic hepatitis. Arch Intern Med. 1981;141(5):623–9.

    Article  PubMed  Google Scholar 

  98. Moro F, Fania L, Sinagra JLM, Salemme A, Di Zenzo G. Bullous pemphigoid: trigger and predisposing factors. Biomolecules. 2020;10(10):1432.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Lai YR, Chang YL, Lee CH, Tsai TH, Huang KH, Lee CY. Risk of non-Hodgkin lymphoma among patients with hepatitis B virus and hepatitis c virus in Taiwan: a nationwide cohort study. Cancers. 2022;14(3) https://doi.org/10.3390/cancers14030583. Large Taiwanese cohort study examining the risk of Non-Hodgkin lymphoma in 37,656 patients with HBV

  100. Ulcickas Yood M, Quesenberry CP Jr, Guo D, Caldwell C, Wells K, Shan J, et al. Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection. Hepatology. 2007;46(1):107–12. https://doi.org/10.1002/hep.21642.

    Article  CAS  PubMed  Google Scholar 

  101. Dogan B. Dermatological manifestations in hepatitis B surface antigen carriers in east region of Turkey. J Eur Acad Dermatol Venereol. 2005;19(3):323–5. https://doi.org/10.1111/j.1468-3083.2004.01185.x.

    Article  CAS  PubMed  Google Scholar 

  102. Song J, Zhang Z, Ji X, Su S, Liu X, Xu S, et al. Lack of evidence of hepatitis in patients with oral lichen planus in China: a case control study. Med Oral Patol Oral Cir Bucal. 2016;21(2):e161–8. https://doi.org/10.4317/medoral.20812.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Bokor-Bratic M. Lack of evidence of hepatic disease in patients with oral lichen planus in Serbia. Oral Dis. 2004;10(5):283–6. https://doi.org/10.1111/j.1601-0825.2004.01029.x.

    Article  CAS  PubMed  Google Scholar 

  104. Nath A, Agarwal R, Malhotra P, Varma S. Prevalence of hepatitis B virus infection in non-Hodgkin lymphoma: a systematic review and meta-analysis. Intern Med J. 2010;40(9):633–41. https://doi.org/10.1111/j.1445-5994.2009.02060.x.

    Article  CAS  PubMed  Google Scholar 

  105. Su T-H, Liu C-J, Tseng T-C, Chou S-W, Liu C-H, Yang H-C, et al. Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma. Aliment Pharmacol Ther. 2019;49(5):589–98. https://doi.org/10.1111/apt.15132.

    Article  PubMed  Google Scholar 

  106. Cheng CL, Huang SC, Chen JH, Wei CH, Fang WQ, Su TH, et al. Hepatitis B surface antigen positivity is an independent unfavorable prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Oncologist. 2020;25(9):793–802. https://doi.org/10.1634/theoncologist.2019-0756. Retrospective cohort study evaluating chronic hepatitis B as a prognostic marker in DLBCL

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Marcucci F, Spada E, Mele A, Caserta CA, Pulsoni A. The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma - a review. Am J Blood Res. 2012;2(1):18–28.

    PubMed  PubMed Central  Google Scholar 

  108. Gonzalez Casas R, Garcia-Buey L, Jones EA, Gisbert JP, Moreno-Otero R. Systematic review: hepatitis-associated aplastic anaemia—a syndrome associated with abnormal immunological function. Aliment Pharmacol Ther. 2009;30(5):436–43. https://doi.org/10.1111/j.1365-2036.2009.04060.x.

    Article  CAS  PubMed  Google Scholar 

  109. Hendren N, Moore J, Hofmann S, Rambally S. Resolution of acute hepatitis B-associated aplastic anaemia with antiviral therapy. BMJ Case Rep. 2017;2017. https://doi.org/10.1136/bcr-2017-221503.

  110. Zeldis JB, Mugishima H, Steinberg HN, Nir E, Gale RP. In vitro hepatitis B virus infection of human bone marrow cells. J Clin Invest. 1986;78(2):411–7. https://doi.org/10.1172/JCI112591.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Yimam KK, Merriman RB, Todd FR. A rare case of acute hepatitis B virus infection causing guillain-barré syndrome. Gastroenterol Hepatol. 2013;9(2):121–3.

    Google Scholar 

  112. Wei J, Duan S. Severe Guillain-Barré syndrome associated with chronic hepatitis B: A case report and literature review. Medicine. 2021;100(48):e27989. https://doi.org/10.1097/md.0000000000027989. Literature review of Guillan-Barre syndrome association with HBV infection

    Article  PubMed  PubMed Central  Google Scholar 

  113. Tsukada N, Koh C-S, Inoue A, Yanagisawa N. Demyelinating neuropathy associated with hepatitis B virus infection: detection of immune complexes composed of hepatitis B virus surface antigen. J Neurol Sci. 1987;77(2):203–16. https://doi.org/10.1016/0022-510X(87)90123-7.

    Article  CAS  PubMed  Google Scholar 

  114. Penner E, Maida E, Mamoli B, Gangl A. Serum and cerebrospinal fluid immune complexes containing hepatitis B surface antigen in Guillain-Barré syndrome. Gastroenterology. 1982;82(3):576–80. https://doi.org/10.1016/S0016-5085(82)80411-3.

    Article  CAS  PubMed  Google Scholar 

  115. Cacoub P, Terrier B. Hepatitis B-related autoimmune manifestations. Rheum Dis Clin North Am. 2009;35(1):125–37. https://doi.org/10.1016/j.rdc.2009.03.006.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    Nilofar Najafian

  2. Pfleger Liver Institute, David Geffen School of Medicine at UCLA, 200 Medical Plaza Suite 214, Los Angeles, CA, 90095, USA

    Steven-Huy Han

Authors
  1. Nilofar Najafian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven-Huy Han
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven-Huy Han.

Ethics declarations

Conflict of Interest

Dr. Najafian declares that she has no conflict of interest. Dr. Han declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Najafian, N., Han, SH. Extrahepatic Manifestations of Hepatitis B. Curr Hepatology Rep 22, 147–157 (2023). https://doi.org/10.1007/s11901-023-00603-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-023-00603-w

Keywords

Search

Navigation